OncoMatch/Clinical Trials/NCT06421376
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Is NCT06421376 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cardonilizumab for esophageal cancer.
Treatment: Cardonilizumab — Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-2N1-3M0-1, CT3/T4N0-3M0-1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any
patients who had previously received other treatments
Lab requirements
Blood counts
hemoglobin (Hb) ≥100g/L; absolute neutrophil count (NEUT)≥1.5×10^9/L; platelets (PLT) ≥100×10^9/L; white blood cell (WBC)≥3.5×10^9/L
Kidney function
serum creatinine (Cr) 1.0×1.5UNL, and BUN≤1.0×UNL
Liver function
ALT and AST ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL
Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g/L ; absolute neutrophil count (NEUT)≥1.5×10^9/L; platelets (PLT) ≥100×10^9/L; white blood cell (WBC)≥3.5×10^9/L,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06421376 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT1-2N1-3M0-1 or CT3/T4N0-3M0-1 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages